RYTM vs ACMR

For growth investors, Rhythm Pharmaceuticals, Inc.

(RYTM) is the stronger pick with 45. 8% revenue growth year-over-year, versus 15. 2% for ACM Research, Inc. (ACMR). ACM Research, Inc. (ACMR) offers the better valuation at 43. 2x trailing P/E (29. 7x forward), making it the more compelling value choice. Analysts rate Rhythm Pharmaceuticals, Inc. (RYTM) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Rhythm Pharmaceuticals, Inc.

(RYTM) delivered a total return of +335. 0%, compared to +133. 4% for ACM Research, Inc. (ACMR). Over 10 years, the gap is even starker: ACMR returned +30. 7% versus RYTM's +220. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Rhythm Pharmaceuticals, Inc.

(RYTM) is the lower-risk stock at 1. 04β versus ACM Research, Inc. 's 3. 24β — meaning ACMR is approximately 210% more volatile than RYTM relative to the S&P 500. On balance sheet safety, ACM Research, Inc. (ACMR) carries a lower debt/equity ratio of 16% versus 177% for Rhythm Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Rhythm Pharmaceuticals, Inc.

(RYTM) is pulling ahead at 45. 8% versus 15. 2% for ACM Research, Inc. (ACMR). On earnings-per-share growth, the picture is similar: Rhythm Pharmaceuticals, Inc. grew EPS 28. 3% year-over-year, compared to -10. 5% for ACM Research, Inc.. Over a 3-year CAGR, RYTM leads at 100. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACM Research, Inc.

(ACMR) is the more profitable company, earning 10. 4% net margin versus -103. 6% for Rhythm Pharmaceuticals, Inc. — meaning it keeps 10. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACMR leads at 12. 1% versus -101. 2% for RYTM. At the gross margin level — before operating expenses — RYTM leads at 89. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RYTM: 45.

5% to $140. 00.

In this comparison, ACMR (0.

2% yield) pays a dividend. RYTM does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Rhythm Pharmaceuticals, Inc.

(RYTM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +220. 8% 10Y return). ACM Research, Inc. (ACMR) carries a higher beta of 3. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RYTM: +220. 8%, ACMR: +30. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RYTM (Healthcare) and ACMR (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.